Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tandem Diabetes Care (TNDM) Research & Development (2016 - 2025)

Historic Research & Development for Tandem Diabetes Care (TNDM) over the last 13 years, with Q3 2025 value amounting to $48.7 million.

  • Tandem Diabetes Care's Research & Development fell 468.04% to $48.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $199.2 million, marking a year-over-year increase of 526.57%. This contributed to the annual value of $198.9 million for FY2024, which is 1721.61% up from last year.
  • Per Tandem Diabetes Care's latest filing, its Research & Development stood at $48.7 million for Q3 2025, which was down 468.04% from $48.1 million recorded in Q2 2025.
  • Tandem Diabetes Care's Research & Development's 5-year high stood at $52.2 million during Q4 2024, with a 5-year trough of $18.0 million in Q1 2021.
  • Its 5-year average for Research & Development is $39.3 million, with a median of $42.2 million in 2023.
  • As far as peak fluctuations go, Tandem Diabetes Care's Research & Development soared by 8462.22% in 2022, and later tumbled by 468.04% in 2025.
  • Quarter analysis of 5 years shows Tandem Diabetes Care's Research & Development stood at $29.5 million in 2021, then grew by 20.66% to $35.6 million in 2022, then grew by 19.72% to $42.6 million in 2023, then grew by 22.52% to $52.2 million in 2024, then decreased by 6.68% to $48.7 million in 2025.
  • Its Research & Development stands at $48.7 million for Q3 2025, versus $48.1 million for Q2 2025 and $50.2 million for Q1 2025.